ASN 002

Drug Profile

ASN 002

Alternative Names: ASN002

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Asana BioSciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours
  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 01 Dec 2016 Asana BioSciences completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02853643)
  • 01 Jul 2016 Asana BioSciences initiates a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02853643)
  • 05 Jun 2015 Preclinical trials in Rheumatoid arthritis in USA (PO) (Asana BioSciences product pipeline, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top